Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.47 |
| ▸ | PLAU | P00749 | 2/20 | 0.47 |
| ▸ | PRKCI | P41743 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 5/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17066470 | 0.81 | TDO2 (0.49) | FLT3GSK3BRXRAGRIN1GRIN2B | |
| SCHEMBL22633214 | 0.78 | MAPK14 (0.43) | FLT3GSK3BRXRAGRIN1GRIN2B | |
| SCHEMBL14947695 | 0.78 | GRM4 (0.48) | ELANEPLAUPRKCIADORA3ALDH1A1 | |
| SCHEMBL23398990 | 0.78 | GAA (0.56) | FLT3GSK3BRXRAGRIN1GRIN2B | |
| SCHEMBL12365100 | 0.78 | ELANE (0.47) | ELANEFLT3GSK3BRXRAGRIN1 | |
| SCHEMBL18254780 | 0.75 | RXRA (0.40) | FLT3GSK3BRXRAGRIN1GRIN2B | |
| SCHEMBL17952503 | 0.75 | GRM4 (0.41) | FLT3GSK3BRXRAGRIN1GRIN2B | |
| SCHEMBL5657776 | 0.74 | P2RX7 (0.44) | FLT3GSK3BRXRAGRIN1GRIN2B | |
| SCHEMBL21484069 | 0.74 | CREBBP (0.41) | PRKCISMN1; SMN2 | |
| SCHEMBL5661512 | 0.74 | ALDH1A1 (0.46) | FLT3GSK3BRXRAGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2025-11-25 | — | — | US | disclosed |
| CN-119564686-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119523983-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119424429-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-115003665-B | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2024-11-08 | — | — | CN | disclosed |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-04 | — | — | US | disclosed |
| CN-117500496-A | Pyrimidine and pyridinamine compounds and their use in the treatment of diseases | 艾匹根生物技术有限公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2023184327-A1 | KINASE INHIBITORS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-10-05 | — | — | WO | disclosed |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | US | disclosed |
| CN-115003665-A | Substituted aminoquinolones as immunoactive DGK alpha inhibitors | 拜耳公司 | 2022-09-02 | — | — | CN | disclosed |
| WO-2021105117-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021105117-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-03 | — | — | WO | disclosed |
| EP-2606031-A2 | AUTOTAXIN INHIBITORS AND USES THEREOF | Amira Pharmaceuticals, Inc. (US) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012024620-A2 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| US-8003626-B2 | in particular fungicidally active; use in agriculture or horticulture for controlling/preventing infestation of plants by phytopathogens; 1-methyl-3-trifluoromethyl-4,5-dihydro-1H-pyrazole-4-carboxylic acid [2-(1,3-dimethyl-butyl)-thiophen-3-yl]-amide | SYNGENTA CROP PROTECTION, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003626-B2 | in particular fungicidally active; use in agriculture or horticulture for controlling/preventing infestation of plants by phytopathogens; 1-methyl-3-trifluoromethyl-4,5-dihydro-1H-pyrazole-4-carboxylic acid [2-(1,3-dimethyl-butyl)-thiophen-3-yl]-amide | SYNGENTA CROP PROTECTION, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20080188442-A1 | Pyrazole-4-Carboxamide Derivatives as Microbiocides | SYNGENTA CROP PROTECTION, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188442-A1 | Pyrazole-4-Carboxamide Derivatives as Microbiocides | SYNGENTA CROP PROTECTION, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| WO-2007009717-A1 | PYRAZOLE-4- CARBOXAMIDE DERIVATIVES AS MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DGKK, DGKG, DGKA | ELANE 3411/4885PLAU 4146/4885PRKCI 46/4885 |
| US-20080188442-A1 | Pyrazole-4-Carboxamide Derivatives as Microbiocides | CD14, FPR1, FPR2 | ELANE 35/4885PLAU 3138/4885PRKCI 3749/4885 |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | DGKK, DGKG, DGKA | ELANE 3411/4885PLAU 4146/4885PRKCI 46/4885 |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | ELANE 3411/4885PLAU 4146/4885PRKCI 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.